Table 2.

Cox proportional analysis for 1-year mortality by eGFR in each age category

eGFR (ml/min per 1.73 m2)<55 yr (n=3034)55−64 yr (n=2699)65−74 yr (n=3329)≥75 yr (n=2206)P for Interaction
Unadjusted model<0.001
 ≥601 [Reference]1 [Reference]1 [Reference]1 [Reference]
 45−592.51 (1.00−6.33)4.72 (2.91−7.65)2.37 (1.74−3.23)1.76 (1.32−2.36)
 30−4410.73 (4.25−27.05)9.93 (5.45−18.10)5.47 (3.97−7.54)3.36 (2.57−4.39)
 <306.90 (3.25−14.65)12.79 (7.74−21.14)7.14 (5.27−9.68)5.15 (3.88−6.83)
Adjusted modela<0.001
≥601 [Reference]1 [Reference]1 [Reference]1 [Reference]
 45−591.87 (0.70−5.00)2.49 (1.47−4.21)1.92 (1.39−2.65)1.62 (1.20−2.19)
 30−445.04 (1.64−15.51)3.76 (1.89−7.49)2.85 (1.98−4.11)2.53 (1.90−3.37)
 <304.84 (1.93−12.15)4.53 (2.42−8.47)3.51 (2.42−5.09)3.30 (2.41−4.52)
Death62 (2.0)108 (4.0)297 (8.9)394 (17.9)
  • Data are presented as hazard ratios (95% confidence intervals) or n (%). eGFR, estimated GFR; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction.

  • a Analyzed confounders included age, sex, body mass index, comorbidities (hypertension, diabetes mellitus, ischemic heart disease, hyperlipidemia, smoking status), Killip class, diagnosis (STEMI versus NSTEMI), percutaneous coronary intervention, and medical treatments during hospitalization.